A new biomarker-based diagnostic test is more effective than current best practice for early detection of adverse outcomes after acute kidney injury, which can be fatal for 50 percent of the critically ill patients who get the condition. A multi-center study reports the kidney injury biomarker NGAL in urine or blood detects early subclinical AKI and its adverse outcomes in critically ill patients.